Distinguishing driver mutations from passenger mutations is critical to the understanding of the molecular mechanisms of carcinogenesis and for identifying prognostic and diagnostic markers as well as therapeutic targets. We reviewed the current approaches and software for identifying driver mutations from passenger mutations including both biology-based approaches and machine-learning^based approaches. We also reviewed approaches to identify driver mutations in the context of pathways or gene sets. Finally, we discussed the challenges of predicting driver mutations considering the complexities of inter-and intra-tumor heterogeneity as well as the evolution and progression of tumors.
INTRODUCTION
In a cancer genome, there often exist hundreds or thousands of various types of mutations [1, 2] . In the past several years, we have observed an explosion of exome and whole-genome sequencing data for various types of cancers. Inundated by this sea of sequencing data, we have come to realize the complexity of the data, mostly notably, the issues of identifying driver mutations among the large number of passenger mutations.
The definitions of driver and passenger mutations were formally introduced by Stratton et al. [3] , who define a driver mutation as a mutation that is directly implicated in carcinogenesis by its ability to confer a Mutationassessor http://mutationassessor.org Predicts functional impacts based on the evolutionary conservation of the affected amino acid in protein homologs. Classifies mutations as 'high', 'medium', 'low' or 'neutral' in terms of functional impact. [5, 6] SIFT (sorting intolerant from tolerant)
http://sift.jcvi.org/ Based on sequence homology, predicts single nucleotide polymorphisms (SNPs) as 'tolerated','damaging' or 'not scored', taking into account position-specific effects.
[7]
SNPs3D http://www.snps3d.org/ Uses protein 3D structural information such as which amino acid substitutions significantly destabilize the folded state of a protein. It also constructs a network of connections (called KnowledgeNet) between genes based on how strongly they are coupled in the literature rather than simple physical interactions.
[8]
PROVEAN (protein variation effect analyzer)
http://provean.jcvi.org Similar to SIFT, but it predicts not only the functional impacts of SNPs but also the functional impacts of indels of single amino acid insertions and 1^10 amino acid deletions [9] Gene ontology similarity score (GOSS)
Predicts how closely the gene in which the variant resides resembles other known cancer-causing genes.
[10]
PMUT http://mmb2.pcb.ub.es:8080/PMut/ Provides prediction by neural networks, which use internal databases, secondary structure prediction and sequence conservation.
[11]
PantherPSEC http://www.pantherdb.org/tools/csnpScoreForm.jsp Calculates the subPSEC (substitution position-specific evolutionary conservation) score based on an alignment of evolutionarily related proteins [12] MAPP http://mendel.stanford.edu/SidowLab/downloads/MAPP Predicts the impact of possible amino acid substitutions on the function of the protein based on the physicochemical variation present in a column of a protein sequence alignment [13] Aggregator methods CanPredict http://www.canpredict.org/ Combines several predictors including SIFT and GOSS and classifies mutations as 'likely-cancer', 'likely-not-cancer' or 'not-determined'. [14] TransFIC (transformed functional impact for cancer) http://bg.upf.edu/transfic/ Integrates the scores from several well-known tools (e.g. SIFT, Polyphen2
and MutationAssessor) to rank the functional impacts of mutations, taking into account the differences in the impacts of the germ line single nucleotide variations (SNVs) of genes that belong to different functional classes.
[15]
Oncodrive-fm http://bg.upf.edu/oncodrive-fm Does not rely on recurrence of mutations and can, therefore, successfully identify candidate cancer drivers with low recurrence.
[ 16] Condel (consensus deleteriousness score of missense SNVs)
http://bg.upf.edu/condel/ Combines the outputs of SIFT, LogRE, MAPP, polyphen2 and MutationAssessor using a weighted approach.
[17]
(continued) growth advantage to tumor cells and is, therefore, positively selected in a mixed cell population and a passenger mutation as a mutation that does not confer a growth advantage to tumor cells and, therefore, will not contribute to the development of cancer. Identifying driver mutations from the background of passenger mutations is critical for understanding the molecular mechanisms of carcinogenesis and for identifying prognostic and diagnostic markers as well as therapeutic targets. In practice, given a set of exome-sequenced/whole-genome-sequenced missense mutations in a cohort samples (usually tumor samples from patient with the same disease), how can one identify the mutations (not just mutated genes) that drive the oncogenesis? Here, we reviewed the approaches and software that have been developed to distinguish driver mutations from passenger mutations.
Approaches for distinguishing driver mutations from passenger mutations Table 1 lists the algorithms for distinguishing driver mutations from passenger mutations that we will cover in this review. In general, there are three categories of methods: (i) methods that are simply based on the prediction of the functional impacts of the mutations; (ii) methods that are based on machine learning that train a classifier based on a known data set of driver and passenger mutations and then apply the parameters to a new dataset; and (iii) methods that are based on the difference in mutation frequencies between driver and passenger mutations.
Methods based on biological differences
The general hypothesis of these approaches is that a driver gene would accumulate a higher frequency (which can be converted to a score) of mutations compared with passenger genes with passenger mutations. Therefore, for each gene containing somatic mutations, their passenger probabilities are determined by calculating statistical scores, usually taking into account the size of the gene, its nucleotide composition, background non-synonymous mutation rates and other relevant factors [1, 23] .
CancerMutationAnalysis
An implementation of this approach was the CancerMutationAnalysis package (http://www. bioconductor.org/packages/2.12/bioc/html/Cancer MutationAnalysis.html) developed by Giovanni Next, the mutation scores at the gene level can be calculated. One method is to calculate the log Likelihood Ratio (logLRT) score, which is the likelihood of observing a particular score in a gene if that gene is a passenger compared with the likelihood of observing it in the real data. Higher scores suggest that the mutation rates are above the passenger rates, which would indicate candidate cancer genes (CAN genes) [1, 2, 24] . The Likelihood Ratio (logLRT) score takes into account the mutation profiles, the total number of nucleotides successfully sequenced for each gene, as well as the estimated background passenger mutation rate.
Other statistical approaches could be applied to calculate the probability of a mutation being a driver mutation versus a passenger mutation. For example, instead of using the log Likelihood Ratio (logLRT) score, Zhang et al. [23] calculated the Mahalanobis distance of a gene from a pool of known cancer genes based on four features: gene size, background non-synonymous mutation rates in normal samples, somatically acquired events and the rate of these events in carriers.
Mutsig
Another implementation of this type of approach is Mutsig (for 'Mutation Significance') (http://www. broadinstitute.org/cancer/cga/mutsig) (unpublished b testing). In Mutsig, the total number of mutations per gene for each tumor is counted and converted into a score. A list of significantly mutated genes can be calculated by setting a threshold by controlling the false discovery rate (FDR).
Machine-learning^based methods
The general basis for these methods is to train a classifier on a known dataset of driver mutations and passenger mutations and then apply the parameters and the classifier to a new data set. In these methods, typically, features related to the missense mutations are extracted, and a classifier is developed using a training data set. The classifier and the parameters are then applied to a new dataset ( Figure 1 ). The classifiers proposed for use in this category of methods include support vector machines, Random Forest and neural network.
CHASM
Carter et al. and Wong et al. [20, 21] developed the cancer-specific high-throughput annotation of somatic mutations (CHASM) to identify driver mutations (Table 1 ). They applied the Random Forest machine-learning method to first learn to distinguish between driver and passenger somatic missense mutations on known training sets of driver mutations and passenger mutations. The driver mutation set was curated from the COSMIC database [25] and from various biological studies showing an oncogenic transformation role in various types of cancers [1, 2, 26, 27] , and the passenger mutation set was generated based on background base substitution frequencies (passenger mutation rates), which were adjusted for the specific tumor type. The features they used included amino acid substitution properties, alignment-based estimates of conservation at the mutated position, predicted local structure at the mutated position and annotations curated from the UniProtKB feature table. The authors applied the method to 607 missense mutations found in a large-scale sequencing analysis of glioblastoma multiforme [26] . They estimated that 8% (49 of the 607 missense mutations) of the mutations were drivers [20] .
DMI (driver mutation identification)
Tan et al. [19] developed a novel missense-mutationrelated feature extraction scheme for 'driver' mutation identification (Table 1 ). The software implementation of the analysis is available at http:// www.methodisthealth.com/software or https://sites. google.com/site/drivermutationidentification/. They proposed a set of 126 candidate predictive features for each missense mutation, including (i) changes in the physiochemical properties of the residues from the mutations; (ii) substitution scoring matrix (SSM) features from published sources; (iii) protein sequence-specific (PSS) features, which extract various patterns of two consecutive amino acid residues or a six-letter exchange group in a protein sequence; and (iv) other annotated features derived from the UniProt KnowledgeBase, Swiss Prot variant page and COSMIC database. A classifier was derived based on the features using a support vector machine (SVM). The classifier was then tested on a new data set using n-fold cross-validation. From the 126 candidate features, they were able to identify the top 70 features that were best able to discriminate between driver and passenger mutations. Most (61 of 70) of the top 70 features consisted of the SSM and PSS features rather than simple changes in the physiochemical properties of the residues from the mutations. They showed that this classifier performs better than the previous methods by comparing their ability (in terms of ROC and prediction precision) to identify 117 EGFR and 1029 TP53 missense mutations [19] .
PolyPhen-2
Adzhubei et al. [4] developed the PolyPhen-2 program. This algorithm includes 11 features (eight sequence-based and three structure-based features) of the mutations as inputs and uses naïve Bayes posterior probability as a classifier. They compiled two data sets to test the program. The first data set, HumDiv, contains 3155 damaging mutations that cause human Mendelian diseases and 6321 sequence variations assumed to be non-damaging based on comparisons between the human and the mammalian homologs of those proteins. The second dataset, HumVar3, contains 13 032 disease-causing mutations from Uniprot and 8946 variations not known to be associated with human disease. They demonstrated that PolyPhen-2 performed better than the original version PolyPhen and three other programs, SIFT, SNAP and SNPs3D. For example, at a false positive rate of 20%, the true positive prediction rates are 92 and 82% for PolyPhen-2 and the original PolyPhen for the HumDiv dataset, respectively [4] .
SNAP (screening for non-acceptable polymorphisms) SNAP (http://rostlab.org/services/snap/) uses a neural network to predict the functional effects of non-synonymous SNPs [22] . It takes the sequence as the input and then retrieves evolutionary information (residue conservation within sequence families), predicted aspects of protein structure (secondary structure, solvent accessibility) and other relevant information for a neural-network-based prediction [22] . It uses the standard feed-forward neural networks with the free parameters of the networks optimized on the training (optimizing connections) and cross-training (optimizing architectures/stop training) sets [22] . A previous study showed that the neural-network-based approach performs slightly better than an SVM-based approach [22] . SNAP performed better (78% accuracy) than SIFT (74%) or PolyPhen (75%) on a test dataset used by those authors [22] . Another advantage is that SNAP can predict gain of function as well as loss of function [22] .
Methods based on the functional impacts of mutations
The hypothesis of this category of methods is that mutations with great functional impacts are more likely to be driver mutations than those with smaller functional impacts. There are many tools with which to predict the functional consequences of a mutation. These tools include SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org/) [7, 28, 29] , SNPs3D (http://www.snps3d.org/) [8] , MutationAssessor (http://mutationassessor.org/) [5, 6] and MAPP [13] (Table 1) .
SNPs3D: SNPs3D (http://www.snps3d.org/) predicts functional impact based on structure and sequence analysis [8] . It has three unique features: first, it uses protein 3D structural information, such as which amino acid substitutions significantly destabilize the folded state of a protein. Second, it constructs a network of connections (termed a KnowledgeNet) between genes based on how strongly they are coupled in the literature rather than on simple physical interactions. Third, it integrates various sources of information such as OMIM, HGMD disease databases, and GO annotation (http://www.geneontology. org/) and provides direct links to them.
SIFT and MutationAssessor both perform a multiple sequence alignment (MSA) based on the evolutionary conservation of the affected amino acid in protein homologs to predict functional impacts [5, 28, 29] . The group who originally developed SIFT recently developed PROVEAN (Protein Variation Effect Analyzer) (http://provean.jcvi.org) [9] . The advantage of the latter is that it predicts not only the functional impacts of SNPs but also the functional impacts of indels of single amino acid insertions and 1-10 amino acid deletions.
Several programs have been developed to integrate or aggregate the output of different prediction programs.
The CanPredict program
The CanPredict program [14] (http://www.canpre dict.org/ or http://www.cgl.ucsf.edu/Research/gen entech/canpredict/) combines several predictors including SIFT [28, 29] , GOSS and a Pfam-based LogR.E-value metric (LogRE) [30] to assess whether a mutation is cancer associated. It classifies mutations as 'likely-cancer', 'likely-not-cancer' or 'notdetermined' [14] .
TransFIC (transformed functional impact for cancer) TransFIC (http://bg.upf.edu/transfic/) [15] integrates the scores from several well-known tools (e.g. SIFT, Polyphen2 and MutationAssessor) to rank the functional impacts of mutations, taking into account the differences in the impacts of the germ line single nucleotide variations (SNVs) of genes that belong to different functional classes.
Oncodrive-fm
Gonzalez-Perez and Lopez-Bigas [16] developed Oncodrive-fm to detect candidate cancer drivers. The program uses the bias toward the accumulation of variants with high-functional impact (named FM bias) observed in a gene or set of genes as an indication of positive selection suggestive of candidate driver genes [16] . The advantage of this program is that it does not rely on recurrence of mutations. For example, genes with few mutations might have high FM bias if all of the mutations are highly deleterious. This program overcomes the limitation of prediction programs based on the recurrence of mutations and can, therefore, successfully identify candidate cancer drivers with low rates of mutation recurrence [16] .
Condel (consensus deleteriousness score of missense mutations)
The Condel program combines the outputs of the SIFT, LogRE, MAPP, polyphen2 and Mutation Assessor programs using a weighted approach [17] . Its developers showed that the Condel program outperforms each of the five individual programs it aggregates. In the Humvar dataset, which contains 12 405 deleterious mutations and 8257 common polymorphisms, the Condel program achieved a prediction accuracy of 88.2%, whereas the accuracies of each individual program varied from 69 to 77.1% [17] .
One drawback of the aforementioned methods is their inability to differentiate mutations that decrease cell fitness from mutations that increase the fitness of cells. Mutations that are damaging to cells would confer the cells fewer advantages compared with the parent cells, thus decreasing fitness. During the evolution of tumors, these mutations, although predicted to have great functional impact, would become dead-end mutations and be wiped out from the surviving tumor cell populations. In our opinion, because of this drawback, these programs would not be sufficient to distinguish driver mutations from passenger mutations and, therefore, are not described in detail in this review. They are, however, listed in Table 1 for the convenience of the readers.
Comparison of the performances of different approaches
Some comparisons of the performance of the various programs have previously been conducted. For example, PolyPhen-2 was shown to perform better than the original PolyPhen and three other programs, SIFT, SNAP and SNPs3D, as noted earlier in the PolyPhen-2 section [4] . Aggregator programs usually perform better than the individual programs that constitute them. As we showed earlier, Condel performed better than each of its input programs (SIFT, LogRE, MAPP, polyphen2 and MutationAssessor) [17] .
Carter et al. [20] compared the performance of the CHASM program with that of Polyphen, SIFT and the CanPredict programs. For the training set as well as the TP53 and EGFR test sets, CHASM performed better than all four of the other programs. For example, for the TP53 test set, the CHASM program has a precision of 98%, whereas the SIFT, PolyPhen (using the PSIC score) and CanPredict programs only achieved 64, 58 and 80% precision, respectively [20] .
The performances of several newly developed program have not been compared; therefore, we compared the performances of CHASM [20] , DMI (Driver Mutation Identification) [19] and TransFic [15] using the data set generated by The Cancer Genome Atlas Research Network (TCGA) for ovarian cancer [31] . CHASM found 207 missense mutations with FDR < 0.25, including mutations reported in their training set. DMI identified 2139 driver mutations with the default parameters. TransFic classified 275 mutations as probably driver mutations (SIFT >1, PPH2 > 0.5, MA > 3). Sixtytwo mutations from five genes (MAP3K7, TP53, MAP2K6, MAP4K3 and MTM1) were selected as drivers by all of the three programs (Figure 2) .
Furthermore, we took TP53 mutations as an example to compare the three methods. The TCGA identified 306 TP53 mutations for ovarian cancers. Among these 306 TP53 mutations, the union of thee methods identified 78 driver mutations: CHASM, DMI and TransFIC each identified 72, 74 and 69 driver mutations, respectively ( Table 2 ). All these three methods are comparable in identifying similar number of driver mutations for the TP53 genes. Among these 306 mutations, 39 were annotated as silent or affecting splicing. Assuming that these 39 mutations are less damaging than other mutations (missense, non-sense or frame-shift), we found that none of these 39 mutations were identified by any of the three methods as driver mutations, suggesting that all three methods have low false-positive identifications of driver mutations.
Mutations enriched in pathways or gene sets
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Pathscan
Wendl et al. [32] developed the Pathscan program to identify significantly mutated pathways ( Table 1) . The program takes into account variations in gene length and resulting differences in genes' mutation probabilities. For multiple samples, they combined individual probabilities into a multiple-sample value using the Fisher-Lancaster theory, with the advantages of improving the differentiation between a few highly mutated genes and many genes having only a few mutations [32] .
MuSiC (mutational significance in cancer)
Dees et al. [18] developed the MuSiC (Mutational Significance in Cancer) pipeline for identifying 'mutational significance' in cancer genomes (Table 1) . MuSiC can not only analyze mutations at the single gene level (i.e. using the SMG 'significantly mutated genes' test), it also integrates the pathscan algorithm [32] for mutation analysis at the pathway level. Another module in MuSiC is the mutation relation test (MRT) module, which tests whether mutations in any two genes act concurrently (positive correlation) or exclusively (negative correlation) [18] . Finally, the clinical correlation test (CCT) module tests for correlations between mutations and clinical features [18] . The CancerMutationAnalysis developed by Boca et al. [33] has unique features enabling it to perform gene set-level analysis by the gene-oriented method or by the patient-oriented method. The patient-oriented method takes into account the private mutations from individual patients. Private mutations also exist at the gene-set level. In the mutation data on glioblastoma multiforme (GBM) patients [26] , 1454 of the 3071 gene sets were altered in at least one sample, and most of them (1131 gene sets, 78%) had only one alteration per sample [33] . Boca et al. [33] demonstrated that the patient-oriented method performs better than the gene-oriented method, as (i) the same gene sets are commonly identified by any two of the patient-oriented methods, but different gene sets are often identified by the gene-oriented method; and (ii) 15 gene sets containing PI3K or RB1 (known to be altered in GBM) were identified as statistically significant by the patient-oriented method, but many gene sets containing PI3K or RB1 were identified as non-significant in the gene-oriented method.
The above three methods only identify genes, pathways or gene sets that contain more mutations than other genes, pathways or gene sets. One should bear in mind that many of the mutations could be, rather than driver mutations, just passenger mutations that are enriched in certain genes, pathways or gene sets.
DISCUSSION Low overlap in predictions among algorithms
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Changing roles of driver and passenger mutations during tumor progression or under changes in the environment
Another challenge is that the passenger and driver mutations might change roles during the evolution of cancers. For example, a driver mutation might give way to another set of driver mutations at the next stage of cancer development or when the cancer is under treatment selection pressure. A preexisting passenger mutation might become a driver mutation. One scenario is when a cancer is subjected to a treatment targeting the driver mutation and develops resistance to the treatment. A mutation that confers resistance to the therapy and growth advantages under the treatment environment might have existed in the original cancer tissue as a passenger mutation in a minor set of cells and then converted to a driver mutation under the selection pressure of the treatment. Cooke et al. [34] analyzed three pairs of high-grade serous (HGS) ovarian cancers before and after platinum resistance had developed and showed that platinum-resistant cells were not linearly derived from the sensitive cells but shared a common ancestor from an early stage of the tumor tissues. Mullighan et al. [35] showed that relapse clones from a small number of acute lymphoblastic leukemia (ALL) patients who relapse after treatment often present as minor subpopulations in the primary tumor at diagnosis, and that genomic abnormalities contributing to ALL relapse are selected for during treatment.. Another scenario is that an initial driver mutation might give way to subsequent driver mutations as the cancer progresses, and that initial mutation no longer contributes to growth advantages in the new stage of carcinogenesis and becomes a passenger mutation.
Deleterious additive effects of passenger mutations
The widely believed assumption that passenger mutations have no role in cancer might not be correct. The fact that many passenger mutations fall within protein-coding genes and other functional elements prompted McFarland et al. [36] to investigate the potential roles of the accumulated efforts of moderately deleterious passengers in cancer. McFarland et al. [36] combined evolutionary simulations of cancer progression with an analysis of cancer sequencing data. They demonstrated that although individually weak, the collective and cumulative effects of the passenger mutations could alter the course of a cancer progression model in ways that are hard to explain with the driver mutation model. They suggested that cancer progression is a balance of driver and passenger mutations, and that treatment approaches that exacerbate the deleterious effects of the passenger mutations be explored [36] .
Challenges with tumor heterogeneity
Significant tumor heterogeneity has been uncovered as more cancer genomes are sequenced. For example, in diffuse large B-cell lymphoma (DLBCL), for which four large-scale genome and exome sequencing efforts have been conducted and data are available for comparisons [23, [37] [38] [39] , the overlap of genes found to contain mutations is only 10-20% among the four studies, and a large portion of the genes identified in each study were not identified in the others [23] . In the two exome sequencing analyses of head and neck cancers [40, 41] , which reported 462 genes and 199 genes as recurrently mutated, only 20 genes overlapped between the two studies. These findings confirmed the possibility that a tumor consists of a heterogeneous mixture of cells at different progression stages and with different somatic mutations. Kan et al. [42] further showed a somewhat surprising finding: that tumors from each individual contain a large number of unique and non-recurrent mutations (so-called private mutations). This understanding was derived from the comprehensive analysis of a cancer genome using next-generation sequencing. Even for mutations of a particular gene in a specific type of cancer, individual tumors often have mutations at different locations. Therefore, intertumor heterogeneity is often driven by private mutations and needs to be considered in identifying driver mutations.
Another complication is intratumor heterogeneity, i.e. the variations within a single tumor for an individual. Intratumor heterogeneity often manifests as clonal heterogeneity, i.e. the existence of distinct clonal tumor populations within a tumor. Currently, most cancer genome sequencing still sequences a bulk tumor tissue sample, which produces the sequence profile that results from averaging all of the cells in the tissue. Different clones of cancer within a cancer tissue might have different properties, such as different mutation rates, subject to selection under different microenvironments. Algorithms for identifying driver mutations that take into account intratumor heterogeneity or incorporate tumor clonal evolution theory still need to be developed.
Challenge in predicting non-exonic mutations
Here, we focus on predictions for the coding regions of genes, as most programs have been developed for that purpose. There are some programs that predict SNPs that affect splicing or transcription factor binding in promoters, but those were excluded from our review. Therefore, predicting impacts on SNPs found in introns, promoters or intronic splicing junctions was not reviewed in this manuscript. Furthermore, we did not cover programs that offer predictions of the impacts of gene fusions, chromosomal rearrangement events or copy number variations (e.g. Oncodrive-CIS [43] , http://bg.upf.edu/ group/projects/oncodrive-cis.php). Therefore, this review is most useful for analyzing data from exome sequencing or data on the exonic regions from whole-genome sequencing.
Key Points
Current approaches and software for identifying driver mutations from passenger mutations. Approaches to identifying driver mutations in the context of pathways or gene sets. Challenges of predicting driver mutations considering the complexities of inter-and intra-tumor heterogeneity as well as the evolution and progression of tumors. 
